These findings underscore the potential confounding impact of CH mutations on the interpretation of tumor-derived mutations in liquid biopsies, when solely relying on the detection of the latter in cfDNA without concurrent sequencing of tumor material or WB, as was previously shown in prostate cancer patients [65]. The gene discussed is C4B; the disease is neoplasm.